The Fort Worth Press - Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories

USD -
AED 3.6725
AFN 64.00019
ALL 82.464942
AMD 358.505756
ANG 1.790403
AOA 917.489175
ARS 1549.869402
AUD 1.483745
AWG 1.8025
AZN 1.700738
BAM 1.779156
BBD 2.017129
BDT 124.690139
BGN 1.77347
BHD 0.378157
BIF 3007.43672
BMD 1
BND 1.291033
BOB 11.682086
BRL 5.781301
BSD 1.001496
BTN 94.002656
BWP 14.018585
BYN 3.009424
BYR 19600
BZD 2.014218
CAD 1.429765
CDF 2318.000039
CHF 0.840235
CLF 0.025339
CLP 997.009842
CNY 6.66455
CNH 6.666165
COP 3318.96
CRC 446.292118
CUC 1
CUP 24.035623
CVE 100.306108
CZK 22.19415
DJF 178.348063
DKK 6.80054
DOP 60.867113
DZD 137.080014
EGP 53.738096
ERN 15
ETB 164.376481
EUR 0.90974
FJD 2.2968
FKP 0.758367
GBP 0.758005
GEL 2.595017
GGP 0.758367
GHS 11.732118
GIP 0.758367
GMD 73.49567
GNF 8873.120921
GTQ 7.654066
GYD 209.544342
HKD 7.846305
HNL 26.932961
HRK 6.831965
HTG 131.250142
HUF 331.948
IDR 18264.5
ILS 3.24665
IMP 0.758367
INR 93.51135
IQD 1518.259596
IRR 1925253.999868
ISK 124.630137
JEP 0.758367
JMD 158.794125
JOD 0.709015
JPY 159.254499
KES 130.039871
KGS 87.449034
KHR 4106.5296
KMF 447.494956
KPW 900.00035
KRW 1335.889958
KWD 0.31175
KYD 0.834633
KZT 445.59873
LAK 22549.202436
LBP 89683.974965
LKR 333.298462
LRD 170.2507
LSL 16.970744
LTL 2.95274
LVL 0.60489
LYD 6.470746
MAD 9.982716
MDL 18.317444
MGA 4555.8128
MKD 55.99778
MMK 2099.8229
MNT 3605.49036
MOP 8.0932
MRU 40.667528
MUR 47.859758
MVR 15.409884
MWK 1736.583325
MXN 18.48035
MYR 4.094801
MZN 63.909759
NAD 16.970667
NGN 1348.790398
NIO 36.851561
NOK 9.6288
NPR 150.403886
NZD 1.81816
OMR 0.384493
PAB 1.001465
PEN 3.415402
PGK 4.572229
PHP 63.72503
PKR 276.920096
PLN 4.00663
PYG 6215.118421
QAR 3.660925
RON 4.864024
RSD 107.010298
RUB 82.424659
RWF 1479.507134
SAR 3.763042
SBD 8.098361
SCR 13.754048
SDG 601.526387
SEK 10.11344
SGD 1.28872
SHP 0.758581
SLE 23.049791
SLL 20969.503664
SOS 572.372042
SRD 37.453499
STD 20697.981008
STN 22.288025
SVC 8.762969
SYP 13002.000337
SZL 16.966036
THB 33.809875
TJS 9.228432
TMT 3.51
TND 3.027513
TOP 2.40776
TRY 50.417255
TTD 6.801694
TWD 32.901301
TZS 2650.013014
UAH 45.525197
UGX 4156.319079
UYU 40.6615
UZS 12027.818082
VES 914.603604
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.750457
XAG 0.020982
XAU 0.000258567304
XCD 2.70255
XCG 1.8049
XDR 0.707052
XOF 596.750457
XPF 108.488699
YER 236.477447
ZAR 16.927155
ZMK 9001.202368
ZMW 20.506056
ZWL 321.999592
SSP 5946.953244
MXV 2.073207
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories
Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories

Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories

Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharmanovia the exclusive commercialization rights to abaloparatide, a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The licensing agreement covers markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.

Text size:

"We are very pleased to enter into a partnership with Pharmanovia with the goal of making abaloparatide available to patients in additional global markets," said Scott Briggs, Chief Executive Officer of Radius. "This collaboration partners two companies that share a commitment to improving the lives of patients with osteoporosis. With Pharmanovia's expertise in osteoporosis and their proven track record of success in these territories, we can look forward to significantly expanding abaloparatide access to patients in need of osteoporosis treatment options."

"We are thrilled to expand our portfolio and bring to the Asia Pacific region such an important and innovative osteoporosis treatment," said James Burt, Chief Executive Officer of Pharmanovia. "This deal recognizes the strength of our commercial model in APAC, and China in particular, where we have one of the leading osteoporosis commercial platforms."

Under the terms of the Licensing Agreement, Radius would be eligible to receive an upfront payment as well as regulatory and commercial milestones plus tiered royalties on net sales.

About Radius:

Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company's presence in bone health.

About Pharmanovia:

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally. We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences. With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas - Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.

Contacts:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: [email protected]

SOURCE: Radius Health

B.Martinez--TFWP